AR113696A1 - Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos - Google Patents

Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos

Info

Publication number
AR113696A1
AR113696A1 ARP180103343A ARP180103343A AR113696A1 AR 113696 A1 AR113696 A1 AR 113696A1 AR P180103343 A ARP180103343 A AR P180103343A AR P180103343 A ARP180103343 A AR P180103343A AR 113696 A1 AR113696 A1 AR 113696A1
Authority
AR
Argentina
Prior art keywords
ilt3
specific antibodies
immunoglobulin type
similar transcript
immunoglobulin
Prior art date
Application number
ARP180103343A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR113696A1 publication Critical patent/AR113696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos monoclonales no promiscuos humanizados específicos para el transcrito similar a la inmunoglobulina tipo 3 (ILT3), también conocido como receptor de tipo inmunoglobulina de leucocitos de la subfamilia B miembro 4 (LILRB4).
ARP180103343A 2017-11-17 2018-11-15 Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos AR113696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762587604P 2017-11-17 2017-11-17

Publications (1)

Publication Number Publication Date
AR113696A1 true AR113696A1 (es) 2020-06-03

Family

ID=64572590

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103343A AR113696A1 (es) 2017-11-17 2018-11-15 Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos

Country Status (26)

Country Link
US (6) US11111297B2 (es)
EP (1) EP3710479A2 (es)
JP (1) JP7194481B2 (es)
KR (1) KR102478433B1 (es)
CN (1) CN111712518A (es)
AR (1) AR113696A1 (es)
AU (1) AU2018367524B2 (es)
BR (1) BR112020009759A8 (es)
CA (1) CA3082409A1 (es)
CL (1) CL2020001240A1 (es)
CO (1) CO2020006405A2 (es)
CR (1) CR20200204A (es)
DO (1) DOP2020000074A (es)
EA (1) EA202091228A1 (es)
EC (1) ECSP20032082A (es)
GE (1) GEP20237565B (es)
IL (1) IL274574A (es)
JO (1) JOP20200131A1 (es)
MA (1) MA50900A (es)
MX (1) MX2020005128A (es)
NI (1) NI202000036A (es)
PE (1) PE20210475A1 (es)
PH (1) PH12020550890A1 (es)
SG (1) SG11202004426SA (es)
TW (1) TWI816715B (es)
WO (1) WO2019099597A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
MX2022007288A (es) 2019-12-19 2022-07-12 Ngm Biopharmaceuticals Inc Agentes de union a ilt3 y metodos de uso de los mismos.
CA3212604A1 (en) * 2021-03-19 2022-09-22 Merck Sharp & Dohme Llc Methods for treating cancer with anti-ilt3 antibodies
WO2023140875A1 (en) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Uses of ilt3-binding agents
TW202346337A (zh) 2022-03-29 2023-12-01 美商恩格姆生物製藥公司 Ilt3及cd3結合劑以及其使用方法
WO2023209716A1 (en) 2022-04-25 2023-11-02 Biond Biologics Ltd. Anti-ilt3 antibodies and use thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
WO2003000199A2 (en) * 2001-06-25 2003-01-03 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2391438A1 (en) 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP1799840A4 (en) * 2004-09-03 2009-02-18 Univ Columbia ILT3-POLYPEPTIDES AND USES THEREOF
CN101213297B (zh) 2005-05-09 2013-02-13 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
RS52860B (en) * 2005-12-20 2013-12-31 Sbi Biotech Co. Ltd. ANTI-ILT7 ANTITELO
WO2007089945A2 (en) 2006-02-02 2007-08-09 The Trustees Of Columbia University In The City Of New York Treating diseases by targeting silt3
EP2041180B8 (en) 2006-06-19 2014-03-05 Liquidating Trust Ilt3 binding molecules and uses therefor
GB0705775D0 (en) 2007-03-26 2007-05-02 Affitech As Product
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
CN101830978A (zh) * 2009-03-09 2010-09-15 中国科学院微生物研究所 一种人免疫球蛋白样受体突变体及其应用
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011120134A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
CA2795078A1 (en) 2010-04-16 2011-10-20 Transbio Ltd Proteins that bind pi16 and uses thereof
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
WO2013033734A1 (en) * 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013181438A2 (en) 2012-05-30 2013-12-05 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating pro-inflammatory immune response
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
US9708406B2 (en) 2013-05-20 2017-07-18 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AU2015319809B2 (en) 2014-09-28 2020-02-06 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016127427A1 (zh) 2015-02-15 2016-08-18 华为技术有限公司 电子设备外壳的加工方法、电子设备外壳及电子设备
KR102129107B1 (ko) 2015-03-06 2020-07-02 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 항-lilrb 항체 및 암의 검출 및 치료를 위한 이의 용도
EP3325006A4 (en) 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York METHOD FOR TREATING CD166-EXPRESSIVE CANCER
MX2018006245A (es) 2015-11-18 2018-08-01 Merck Sharp & Dohme Proteinas de union a pd1 y/o lag3.
US11249081B2 (en) * 2016-08-31 2022-02-15 Agency For Science, Technology And Research Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof
WO2018089300A1 (en) 2016-11-10 2018-05-17 Merck Sharp & Dohme Corp. Ilt3 ligand
CA3053164A1 (en) 2017-02-09 2018-08-16 Bluefin Biomedicine, Inc. Anti-ilt3 antibodies and antibody drug conjugates
CA3212604A1 (en) * 2021-03-19 2022-09-22 Merck Sharp & Dohme Llc Methods for treating cancer with anti-ilt3 antibodies
AU2022318734A1 (en) * 2021-07-28 2024-02-08 Merck Sharp & Dohme Llc Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
WO2023017525A1 (en) * 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
WO2023159152A2 (en) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor
WO2023235699A1 (en) * 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2024026019A1 (en) * 2022-07-28 2024-02-01 Merck Sharp & Dohme Llc Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies

Also Published As

Publication number Publication date
CN111712518A (zh) 2020-09-25
US20190153093A1 (en) 2019-05-23
ECSP20032082A (es) 2020-08-31
BR112020009759A8 (pt) 2023-01-31
KR102478433B1 (ko) 2022-12-15
US20220025042A1 (en) 2022-01-27
EA202091228A1 (ru) 2020-08-12
US20220025043A1 (en) 2022-01-27
TW201922786A (zh) 2019-06-16
GEP20237565B (en) 2023-11-10
CO2020006405A2 (es) 2020-06-09
JOP20200131A1 (ar) 2020-05-28
EP3710479A2 (en) 2020-09-23
WO2019099597A3 (en) 2019-06-13
AU2018367524B2 (en) 2022-09-15
CR20200204A (es) 2020-06-18
JP7194481B2 (ja) 2022-12-22
CL2020001240A1 (es) 2020-12-18
AU2018367524A1 (en) 2020-06-11
MX2020005128A (es) 2020-07-27
PH12020550890A1 (en) 2021-04-12
KR20200083598A (ko) 2020-07-08
DOP2020000074A (es) 2020-08-31
US20220010011A1 (en) 2022-01-13
NI202000036A (es) 2020-09-24
SG11202004426SA (en) 2020-06-29
JP2021503280A (ja) 2021-02-12
US11111297B2 (en) 2021-09-07
MA50900A (fr) 2020-09-23
CA3082409A1 (en) 2019-05-23
BR112020009759A2 (pt) 2020-11-03
PE20210475A1 (es) 2021-03-08
TWI816715B (zh) 2023-10-01
US20220010010A1 (en) 2022-01-13
IL274574A (en) 2020-06-30
US20220033497A1 (en) 2022-02-03
WO2019099597A2 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
ECSP20032082A (es) Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos
BR112022010206A2 (pt) Receptores de antígeno quiméricos e usos dos mesmos
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
BR112017020894A2 (pt) imunoreceptores específicos claudina-18.2 e epítopos de células t
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
CY1121539T1 (el) Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
AR105767A1 (es) Proteínas de fusión de unión a gitr multivalentes y multiespecíficas
CL2019000628A1 (es) Anticuerpos anti-pd-1 y sus usos.
MX2018008308A (es) Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
CO2017006740A2 (es) Anticuerpos anti–cd79b
CO2019011155A2 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
CO2018001405A2 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
CL2020002613A1 (es) Receptores quiméricos de dll3 y métodos para su uso
UA116479C2 (uk) БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
CL2018003515A1 (es) Anticuerpos anti-gitr y sus usos.
CR20180141A (es) Anticuerpos anti-cd 19 humano humanizados y métodos de utilización
CL2018002898A1 (es) Nuevos anticuerpos anti-sirpa y sus aplicaciones terapéuticas.
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
NZ741067A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
IL284091A (en) Antibodies neutralize the type 2 immunoglobulin-like leukocyte receptor
BR112018006991A2 (pt) receptores de antígeno quiméricos direcionados ao psca
CL2018002639A1 (es) Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn.